NON-ALCOHOLIC STEATOHEPATITIS

This early-stage study tested a new medicine, ARO-HSD, in 50 people—some healthy and some with NASH (a serious fatty liver disease). The main goal was to see if the drug is safe and how the body processes it. This is not a cure; it's a first step to see if the drug can be given s…

This early-stage trial tested a new oral drug called J2H-1702 in 100 healthy men to see if it is safe and how the body processes it. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. Participants received either the drug or a pla…

This study tested whether combining a new liver medicine (NNC0194-0499) with semaglutide (a diabetes and weight-loss drug) can reduce liver scarring in people with non-alcoholic steatohepatitis (NASH). About 698 adults received weekly injections of either the combo, a placebo, or…

This study tested an experimental drug called MGL-3196 in 125 adults with non-alcoholic steatohepatitis (NASH), a serious liver disease caused by fat buildup. The goal was to see if the drug could reduce liver fat compared to a placebo over 12 weeks. Participants took a daily pil…

This early-phase study tested an oral drug called idebenone in 53 adults with non-alcoholic steatohepatitis (NASH) and mild-to-moderate liver scarring. The main goal was to check safety and tolerability, while also looking for signs that the drug might reduce liver stiffness and …

This study tested a new drug called J2H-1702 in 87 adults with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. The goal was to see if the drug is safe and if it can reduce liver fat and scarring after 12 weeks compared to a placebo. Participants were randomly…

This study tested whether a special ultrasound feature can measure liver fat as accurately as an MRI. 60 adults with or at risk for fatty liver disease had both an ultrasound and an MRI. The goal was to see if the simpler, cheaper ultrasound could give reliable results.

This study tested a new ultrasound feature that measures liver fat in children with or at risk for fatty liver disease. Researchers compared the ultrasound results to MRI scans, which are the current standard but more expensive and time-consuming. The goal was to see if the simpl…

This study checked if a special MRI scan called LiverMultiScan gives the same results when repeated on the same machine or on different machines. 61 adults with various liver conditions were scanned multiple times. The goal was to see if the scan reliably measures liver fat, iron…

This study looked at how the drug efinopegdutide is processed in people with moderate to severe liver damage compared to healthy people. Researchers measured drug levels in the blood and checked for side effects in 22 participants. The goal was to understand if liver problems cha…

This study examined medical records of 263 adults with NASH to see how factors like age, other health problems, and medications relate to the severity of liver scarring. The goal was to identify which patients are at higher risk for advanced fibrosis. The findings may help doctor…

This early-stage study tested the safety of a new drug called ACT500 in 72 healthy Chinese adults. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moves through the body. The goal was not to treat disease but to gath…

This early-phase trial tested a single dose of J2H-1702 in 16 healthy women aged 19-45 to see if it is safe and how the body processes it. The study did not involve people with NASH (a liver disease) and was designed to gather basic safety and drug-level information. Results will…

This study tested whether a pop-up alert in electronic medical records could help doctors refer patients with fatty liver disease to liver specialists. Thirty doctors from internal medicine, family medicine, and endocrinology took part. The goal was to see if the alert increased …